Low zinc levels in patients with COVID-19

This study reveals that patients with COVID-19 and low blood levels of Zinc have higher mortality and a longer recovery period

Description of the Study:

  • Title: Low Zinc Levels at Admission Associates with Poor Clinical Outcomes in SARS-CoV-2 Infection.
  • Principal Investigators: Marina Vogel González, Marc Talló Parra, Víctor Herrera Fernández, Gemma Pérez Vilaró, Miguel Chillón, Xavier Nogués, Silvia Gómez Zorrilla, Inmaculada López Montesinos, Isabel Arnau Barrés, Maria Luisa Sorli Redó, Juan Pablo Horcajada, Natalia García Giralt, Julio Pascual, Juana Díez, Rubén Vicente and Robert Güerri Fernández.
  • Center of Implementation: Hospital del Mar in Barcelona.
  • Study Population: All patients admitted with COVID-19 for ≥48 h between 9 March and 1 April 2020 in Hospital del Mar.
  • Study Type: Retrospective observational cohort study.
  • Methods: Demographic, clinical, epidemiological, and the whole-episode (laboratory workup, vital signs, treatment) data were extracted from electronic medical records using a standardized data collection method.

Objectives of the Study:

Principal Objective: To demonstrate the association between the zinc status of hospitalized COVID-19 patients with disease progression and clinical outcomes.

More about this Study:

Background: Zinc is an essential micronutrient that impacts host–pathogen interplay at infection. Zinc balances immune responses, and also has a proven direct antiviral action against some viruses. Importantly, zinc deficiency is a common condition in elderly and individuals with chronic diseases, two groups with an increased risk for severe severe coronavirus disease 2019 (COVID-19) outcomes.

Conclusions: This analysis has shown a robust correlation between low SZC and COVID-19 severity and mortality. The cause is likely to be a combination of immune system imbalance and a direct benefit of viral replication. Thus, we propose SZC as a novel and additional parameter to predict COVID-19 outcome. It is then urgent to start clinical trials supplementing patients with low SZC at admission with zinc to reestablish zinc homeostasis. It should be also recommended to promote zinc supplementation programs targeted to people at risk of zinc deficiency, such as the elderly, in order to reduce COVID-19’s severity.

Logo Hospital Del Mar

Other Epidemiological Studies:


Clinical trial designed to evaluate the safety and immunogenicity of a dose of Comirnaty vaccine (Pfizer) in people who have previously received a dose of…

E-speranza-COVID19 Project

This study aims to demonstrate efficacy of Montelukast for patients with persistent COVID-19 to help them improve their quality of life.

ANTICOV Study: COVID-19 in Africa

Collaborate with ANTICOV study to treat COVID-19 in Africa.

COnV-ert study, convalescent plasma to stop COVID-19

Early administration of convalescent plasma in people over 50 years of age with mild to moderate COVID-19 disease may slow disease progression and decrease the…

An antiviral mouthwash and COVID-19

Using a mouthwash containing β-cyclodextrin and citrox (bioflavonoids) (CDCM), available in pharmacies, helps reduce the SARS-CoV-2 viral load in saliva.

Pediatric COVID vaccination clinical trial

This pediatric clinical trial aims to test the safety, tolerability and immunogenicity of Pfizer's COVID vaccine in children under 12 years of age.

LacCOVID Study

The LacCOVID study has shown that milk from lactating women who have been vaccinated with Pfizer-BioNTech contains specific antibodies against the SARS-CoV-2 coronavirus.

Immunomodulatory Treatment In Patients With Severe Pneumonia COVID-19

Clinical trial to perform immunomodulatory treatment in adult patients with severe COVID-19 pneumonia with the aim of helping to define the standard treatment for this…

Prevention With Calcifediol Of Respiratory Problems Caused By COVID-19

This multicentre clinical trial aims to demonstrate that treatment with Calcifediol reduces the need for invasive ventilation and Intensive Care Unit admissions and deaths.

Maraviroc in patients hospitalized for COVID-19

Phase II clinical trial evaluating the safety and efficacy of the drug Maraviroc combined with standard therapy versus standard therapy in patients infected with SARS-CoV-2…